Log in to save to my catalogue

Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 tr...

Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 tr...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2560960465

Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial

About this item

Full title

Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial

Publisher

New York: Nature Publishing Group US

Journal title

Nature medicine, 2021-08, Vol.27 (8), p.1410-1418

Language

English

Formats

Publication information

Publisher

New York: Nature Publishing Group US

More information

Scope and Contents

Contents

Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has shown activity in melanoma, but has not been previously evaluated in metastatic non-small cell lung cancer. We conducted a single-arm open-label phase 1 trial (
NCT03215810
) of TILs administered with nivolumab in 20 patients with advanced non-small cell lung cancer followi...

Alternative Titles

Full title

Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2560960465

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2560960465

Other Identifiers

ISSN

1078-8956

E-ISSN

1546-170X

DOI

10.1038/s41591-021-01462-y

How to access this item